Conference Call Scheduled for Wednesday, October 23 at 4:30 p.m. Eastern
Time
SAN
DIEGO, Oct. 16, 2024 /PRNewswire/ -- Viking
Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage
biopharmaceutical company focused on the development of novel
therapies for metabolic and endocrine disorders, today announced
that the company will release financial results for the third
quarter 2024 after the market close on Wednesday, October 23, 2024.
The company will host a conference call to discuss financial
results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, October 23,
2024. To participate on the conference call, please dial (844)
850-0543 from the U.S. or (412) 317-5199 from outside the U.S. In
addition, following the completion of the call, a telephone replay
will be accessible until October 30,
2024, by dialing (877) 344-7529 from the U.S. or (412)
317-0088 from outside the U.S. and entering replay access code
#9473630. Those interested in listening to the conference call
live via the internet may do so by visiting the Webcasts page of
Viking's website at http://ir.vikingtherapeutics.com/webcasts. An
archive of the webcast will also be available on the Webcasts page
of the company's website for 30 days.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on the development of novel first-in-class or
best-in-class therapies for the treatment of metabolic and
endocrine disorders, with three compounds currently in clinical
trials. Viking's research and development activities leverage
its expertise in metabolism to develop innovative therapeutics
designed to improve patients' lives. Viking's clinical
programs include VK2735, a novel dual agonist of the glucagon-like
peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide
(GIP) receptors for the potential treatment of various metabolic
disorders. Data from a Phase 1 and a Phase 2 trial evaluating
VK2735 (dosed subcutaneously) for metabolic disorders demonstrated
an encouraging safety and tolerability profile as well as positive
signs of clinical benefit. Concurrently, the company is evaluating
an oral formulation of VK2735 in a Phase 1 trial. Viking is also
developing VK2809, a novel, orally available, small molecule
selective thyroid hormone receptor beta agonist for the treatment
of lipid and metabolic disorders. The compound successfully
achieved both the primary and secondary endpoints in a recently
completed Phase 2b study for the treatment of
biopsy-confirmed non-alcoholic steatohepatitis (NASH) and
fibrosis. In a Phase 2a trial for the treatment of
non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C,
patients who received VK2809 demonstrated statistically significant
reductions in LDL-C and liver fat content compared with patients
who received placebo. The company's newest program is
evaluating a series of internally developed dual amylin and
calcitonin receptor agonists (or DACRAs) for the treatment of
obesity and other metabolic disorders. In the rare disease
space, Viking is developing VK0214, a novel, orally available,
small molecule selective thyroid hormone receptor beta agonist for
the potential treatment of X-linked adrenoleukodystrophy
(X-ALD). In a Phase 1b clinical trial in patients
with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was
shown to be safe and well-tolerated, while driving significant
reductions in plasma levels of very long-chain fatty acids (VLCFAs)
and other lipids, as compared to placebo.
For more information about Viking Therapeutics, please
visit www.vikingtherapeutics.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-report-financial-results-for-third-quarter-2024-on-october-23-2024-302276687.html
SOURCE Viking Therapeutics, Inc.